Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00189163 · ClinicalTrials.gov registry record · Phase 4

Pioglitazone in Hepatitis C

A Phase 4 study of Chronic Hepatitis C, sponsored by University of Michigan.

Completed
Registry status
Phase 4
Development phase
40
Enrollment target
1
Study location

NCT00189163: Completed Phase 4 study of Chronic Hepatitis C, sponsored by University of Michigan.

NCT00189163 is a Phase 4 study of Chronic Hepatitis C that has completed, run by University of Michigan. The registered enrollment target is 40 participants, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00189163, a Phase 4 study of Chronic Hepatitis C, has completed, sponsored by University of Michigan.

COMPLETED
Registry status
Phase 4
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

The presence of insulin resistance (IR) appears to be a key factor in the development of steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1 infections similar to levels in Non-alcoholic fatty liver disease (NAFLD). The objective of this study is to determine whether Pioglatizone, when given along with Interferon and Ribavirin, reduces insulin resistance and lowers HCV viral levels and improved response in patients who have HCV genotype-1 infection when compared to a placebo.

Primary Outcome

Measuring HCV RNA in serum (detectable or undetectable)

Conditions Studied

Interventions

  • DRUG Pioglitazone
  • DRUG Placebo Oral Tablet

Study Locations (1)

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2005-01
Phase Phase 4
University of Michigan

1,327 total trials

What the finished NCT00189163 record still lists

NCT00189163 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 212-participant average among 16 other Chronic Hepatitis C trials with a reported enrollment target (81% lower).

The record links to 1 condition, with Chronic Hepatitis C appearing as the primary indexed condition, and to 2 interventions - of which Pioglitazone is the first listed.

NCT00189163 reports a single indexed study location in Michigan.

Frequently Asked Questions

What is clinical trial NCT00189163 about?

NCT00189163 is a clinical study titled "Pioglitazone in Hepatitis C". The presence of insulin resistance (IR) appears to be a key factor in the development of steatosis and disease progression in patience with Hepatitis C virus (HCV) genotype-1 infections similar to levels in Non-alcoholic fatty liver disease (NAFLD). The objective of this study is to determine whethe...

What is the current status of trial NCT00189163?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2005-01.

What conditions does trial NCT00189163 study?

This clinical trial studies the following conditions: Chronic Hepatitis C.

What interventions are being tested in trial NCT00189163?

The interventions under investigation include: Pioglitazone (DRUG), Placebo Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT00189163?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00189163 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Hepatitis C

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00189163's enrollment target sits among peer trials

40 9th of 16 higher than 7 of 16 other Chronic Hepatitis C trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Hepatitis C trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00189163, the US trial registry maintained by the National Library of Medicine. NCT00189163 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.